Groups

Research Focus

Ld - Advanced Practice Providers; Nurse Practitioner

Recent additions – View all

1. Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma

   Journal Article

   Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
   Liver Cancer (2025)

   Fulltext@MSK | Save
2. Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC)

   Meeting Abstract

   Abou-Alfa, G. K.; Meyer, T.; Zhang, J.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Xu, F.; Eli, L. D.; Harding, J. J.; O'Reilly, E. M.; more...
   Journal of Clinical Oncology (2021)

   Fulltext@MSK | Save